MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Editas Medicine, Inc. - Common Stock (NQ:EDIT)

2.980 +0.100 (+3.47%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Editas Medicine, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
What Really Mattered With Editas Medicine's Q1 Update ↗
It wasn't the biotech's financial performance. 
Via The Motley Fool
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021 ↗
Upgrades For Genuine Parts Co (NYSE:GPC), Goldman Sachs upgraded the previous rating of Sell to Neutral. In the first quarter, Genuine Parts showed an EPS of $1.50,... 
Via Benzinga
News headline image
Best Biotech Stocks & ETFs for mRNA, Gene Editing ↗
2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 4) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Jaguar Health (NASDAQ:JAGX) shares moved upwards by 11.8% to $1.61 during Friday's pre-market session. The market value of their outstanding shares is at $205.... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
Gainers INmune Bio (NASDAQ:INMB) stock rose 26.18% to $13.59 during Monday's regular session. As of 08:06 EST, this security is trading at a volume of 560.6K shares,... 
Via Benzinga
News headline image
CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today ↗
A "sell" rating is one thing, but a 50% price target? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it. 
Via InvestorPlace
News headline image
Nasdaq Stays Flat as Workhorse Drives Higher, Editas Sinks ↗
Investors are trying to figure out which stocks have the best prospects. 
Via The Motley Fool
Topics Stocks
News headline image
54 Biggest Movers From Friday ↗
Gainers Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares surged 73.9% to close at $31.30 on Friday after the company priced its IPO at $18 per share. General Finance... 
Via Benzinga
Topics Initial Public Offering
News headline image
Why Editas Medicine Stock Is Getting Crushed Today ↗
Investors are running for the hills following this analyst take on the biotech's prospects. 
Via The Motley Fool
News headline image
38 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) shares jumped 78.1% to $32.06 after the company priced its IPO at $18 per share. General Finance Corporation (NASDAQ: GFN)... 
Via Benzinga
Topics Initial Public Offering
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021 ↗
Upgrades According to Argus Research, the prior rating for United Airlines Holdings Inc (NASDAQ:UAL) was changed from Hold to Buy. In the fourth quarter, United Airlines... 
Via Benzinga
News headline image
3 Biotech Stocks Ripe for Spring Portfolio Cleaning ↗
All down 45% or more from their 52-week highs, should you consider cutting your losses? 
Via The Motley Fool
News headline image
Biotech Stocks Hit A Snag — Why Experts Say The Heyday Isn't Over ↗
Regulatory and drug-pricing worries have knocked biotech stocks off their pedestal. After hitting a high point in February, biotech stocks have fallen 20%. 
Via Investor's Business Daily
News headline image
Spring Cleaning for Investors ↗
Start this year's spring cleaning by asking yourself the right questions. 
Via The Motley Fool
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story